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Summary
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified
BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine
kinase inhibitor imatinib. Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.
Mutations fell into two groups—those that alter amino acids that directly contact imatinib and those postulated to prevent
BCR-ABL from achieving the inactive conformational state required for imatinib binding. Distinct mutations conferred
varying degrees of imatinib resistance. Mutations detected in a subset of patients with stable chronic phase disease
correlated with subsequent disease progression. Multiple independent mutant clones were detected in a subset of relapsed
cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.
Introduction CML achieve hematologic responses to imatinib, and the Ph
chromosome is no longer detected in about 50% of these pa-
The tyrosine kinase BCR-ABL is the fusion product of a recipro- tients using standard cytogenetic assays (termed cytogenetic
cal chromosome translocation between chromosomes 9 and response) (Druker et al., 2001b; Kantarjian et al., 2002). Approxi-
22, known as the Philadelphia (Ph) chromosome, and is present mately 60% of patients with advanced-stage CML (blast crisis)
in the leukemic cells of more than 95% of patients with chronic respond to imatinib, but nearly all these patients relapse despite
myeloid leukemia (CML) (Sawyers, 1999). The ability of BCR- continued therapy (Druker et al., 2001a; Sawyers et al., 2002).
ABL to produce a CML-like disease in mouse models (Daley et We previously demonstrated that BCR-ABL kinase activity is
inhibited in leukemic cells at the time of response but is reacti-al., 1990; Elefanty et al., 1990; Kelliher et al., 1990) led to efforts
to develop inhibitors of its kinase activity. Imatinib (STI571, vated at relapse (Gorre et al., 2001a). This result suggested that
BCR-ABL maintains a crucial role throughout disease progres-Gleevec) was approved for CML treatment after striking efficacy
was demonstrated in all stages of the disease (Druker et al., sion in CML. Detailed analysis of 11 such patients revealed at
least two distinct mechanisms for resistance—BCR-ABL gene2001a, 2001b; Kantarjian et al., 2002; Sawyers et al., 2002;
Talpaz et al., 2002). The clinical success of this small molecule amplification or point mutations in the kinase domain that pre-
sumably interfere with drug-protein binding without compromis-kinase inhibitor has led to the notion that other selective tyrosine
kinase inhibitors may have significant activity against a range ing kinase activity (Gorre et al., 2001a). While these findings
have been confirmed in additional small studies (Branford etof human malignancies.
Ninety percent of patients with early-stage (chronic phase) al., 2002; Hofmann et al., 2002; von Bubnoff et al., 2002), there is
S I G N I F I C A N C E
Chronic myelogenous leukemia represents the first human malignancy to be successfully treated with a small molecule tyrosine
kinase inhibitor. Clinical resistance to this inhibitor (imatinib) has been reported in small numbers of patients due to BCR-ABL gene
mutation or amplification. Here we present a comprehensive analysis of CML patients in varying stages of disease that documents
a very high frequency of BCR-ABL kinase domain mutations in patients that develop imatinib resistance. These results reinforce the
central importance of BCR-ABL in the pathogenesis of this disease, even at the most advanced stages, and define the challenges
necessary to design second generation targeted therapies. Our findings may also have implications for other kinase inhibitors
currently in development against a broad range of cancers.
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disagreement about the frequency with which mutations occur specificity of our methodology, a mutation was deemed present
if it was detected on both strands of DNA in two independent(Barthe et al., 2001; Hochhaus et al., 2001). In addition, other
mechanisms of imatinib resistance have been proposed, such isolates from the same patient (therefore representing approxi-
mately 20% of the total population of BCR-ABL mRNA tran-as drug sequestration mediated by the serum protein -1 acid
glycoprotein (AGP) (Gambacorti-Passerini et al., 2000), or drug scripts).
Samples from 32 CML patients who relapsed after a hemato-efflux by multidrug resistance pumps (Mahon et al., 2000). To
date, neither of the latter mechanisms has been implicated in logic response to imatinib were analyzed (16 with myeloid blast
crisis, 5 with lymphoid blast crisis, and 11 with chronic phase).patients (Jorgensen et al., 2002).
Clinical efforts to overcome imatinib resistance must begin Mutations were identified at the time of relapse in 29 of the 32
patients (15 of 16 with myeloid blast crisis, 4 of 5 with lymphoidby defining the most common mechanisms of resistance in a
larger number of patients. As a first step, we conducted compre- blast crisis, and 10 of 11 with chronic phase) (Table 1). Mutations
mapped to 13 different amino acid residues in the ABL kinasehensive BCR-ABL kinase domain sequencing analysis of 45
CML patients who demonstrated imatinib resistance. Mutations domain and predicted 15 different codon changes (Figure 1).
Nucleotide changes affecting two residues, Q252 and Y253,were detected in over 90% of patients (29 of 32) who relapsed
after an initial response to imatinib, including those with chronic led to two alternative amino acid substitutions each—Q252H/R
and Y253F/H. Mutations in seven of these residues have beenphase, myeloid blast crisis, and lymphoid blast crisis CML. Mu-
tations led to 15 amino acid substitutions in 13 different residues reported in smaller studies (Branford et al., 2002; Gorre et al.,
2001a; Hofmann et al., 2002; von Bubnoff et al., 2002); sixwhich, based on known crystal structure data, include direct
drug contact sites as well as sites that presumably impair the mutations detected are novel. Mutations were detected at each
of the variable (X) amino acids of the kinase consensus sequenceconformational change in the kinase domain required to accom-
modate imatinib binding. Mutant BCR-ABL alleles retain bio- Gly-X-Gly-X-X-Gly-X-Val located in the P loop, which provides
a number of important contacts for ATP binding. One of theselogic activity but show varying degrees of resistance to imatinib
in biochemical and biological assays. Mutations were also de- mutations, E255K, in addition to mutations T315I and M351T,
accounted for over 60% of the cases. To address whether thetected in 4 of 13 chronic phase patients with stable disease
and correlated with subsequent clinical relapse. Additional ob- high frequency and variety of kinase domain mutations repre-
sented artifact introduced during the PCR amplification process,servations that multiple independent imatinib-resistant clones
were detected in some patients (polyclonal resistance) and that we sequenced ten independent subclones of the ABL kinase
domain obtained from each of two healthy blood donors. Usingkinase domain mutations were detected prior to treatment in
some patients with imatinib-refractory myeloid blast crisis pro- our criteria of at least two independent isolates out of ten clones,
we found no evidence of ABL kinase domain mutation. Wevide evidence that mutations develop as a consequence of
clonal selection rather than generalized hypermutability. Collec- therefore conclude that the BCR-ABL kinase domain mutations
described here are unlikely to be the result of PCR-introducedtively these results establish the primary role of BCR-ABL kinase
domain mutations as a cause of imatinib resistance in CML error.
To gain insight into potential mechanisms by which theseand provide evidence that knowledge of mutation status might
influence clinical management. The spectrum of mutations iden- mutations might confer imatinib resistance, we modeled each
amino acid substitution onto the known cocrystal structure oftified provides new insights into kinase domain function and
into novel treatment strategies to overcome resistance. the ABL kinase domain bound to imatinib (Figure 2A; Nagar et
al., 2002; Schindler et al., 2000). The mutations fall into two
groups. The first group includes mutations at sites that directlyResults
contact imatinib (T315, F317, and F359) and presumably impair
drug binding without significantly affecting the binding of ATPKinase domain mutations are detected in 90% of CML
patients who relapse after responding to imatinib (Figure 2A, red spheres). The second group includes mutations
in residues located in distinct regions, all of which are implicatedThe ability to detect BCR-ABL mutations in imatinib-resistant
CML cells is dependent on patient selection and the sensitivity in the unique conformational change that the kinase domain
must undergo to accommodate imatinib. For example, the ATPof the assay used. Because the Ph chromosome translocation
occurs in a pluripotent hematopoietic stem cell, nearly all the phosphate binding loop (P loop) is distorted in the imatinib/ABL
structure such that it forms a hydrophobic cage for the drug.blood and bone marrow cells in untreated CML patients express
the BCR-ABL fusion gene. In patients with a hematologic response Resistance mutations observed in the P loop region (G250,
Q252, Y253, and E255) are likely to destabilize the distortedto imatinib (normalization of blood counts) and a cytogenetic
response (reduction in the fraction of Ph chromosome-con- shape (Figure 2A, green spheres). Y253 inserts into the ATP
binding site, forming one wall of a hydrophobic pocket for thetaining cells), a significant fraction of the BCR-ABL-expressing
cells isolated at the time of relapse will represent the drug- drug, and is stabilized by hydrogen bonds formed by the hy-
droxyl group of the side chain (Figure 2B). Y253H/F substitutionsresistant clone. However, in patients who relapse on imatinib
after a hematologic response but no cytogenetic response, ima- would break the hydrogen bonding interactions of the tyrosine
side chain, which is also specific for the distorted conformationtinib-resistant cells represent only a subset of the total BCR-
ABL-expressing cells (often 20% or less) (Gorre et al., 2001b). of the P loop. E255 forms hydrogen bonds that bridge the side
chains of K247 and Y257, an interaction that appears to beTo optimize the sensitivity of mutation detection, we performed
RT-PCR amplification of BCR-ABL mRNA from CML patient specific to the distorted conformation of the P loop. Mutation
of E255 presumably destabilizes the P loop conformation thatblood or bone marrow cells, subcloned the PCR products (rather
than sequence the products directly), and sequenced ten inde- is required for imatinib binding.
A second structural change required for imatinib binding ispendent PCR products per patient sample. To improve the
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Table 1. Detailed summary of BCR-ABL kinase domain mutations by disease category prior to imatinib therapy
Duration of treatment with imatinib BCR-ABL kinase Number of independent clones
Patient no. at time of analysis domain mutation(s) containing mutation
1 MBC 4.5 months G250E 7/10
H396R 2/10
2 MBC 13 months T315I 10/10
3 MBC 8 months none n/a
4 MBC 3.5 months M351T 5/10
5 MBC 2 months Q252H 5/10
6 MBC 13 months M351T 8/10
7 MBC 13 months M351T 6/10
8 MBC 5 months E255K 4/10
Y253H 2/10
9 MBC 7 months E355G 5/10
F317L 2/10
10 MBC 6 months G250E 8/10
11 MBC 3 months Y253F 3/10
E255K 2/10
M351T 2/10
H396R 2/10
12 MBC 2 months M351T 3/10
T315I 2/10
Y253H 2/10
E255K 2/10
13 MBC 3 months Y253F 2/10
E255K 2/10
T315I 2/10
14 MBC 3 months E255K 2/10
15 MBC 2 months E255K 2/10
Q252H 2/10
16 MBC 4 months F359V 8/10
17 LBC 2 months M351T 3/10
E255K 2/10
T315I 2/10
Y253F 2/10
18 LBC 3 months T315I 5/10
E255K 2/10
Q252R 2/10
19 LBC 2 months T315I 5/10
20 LBC 9 months T315I 6/10
21 LBC 3 months none n/a
22 CP 17 months T315I 8/10
23 CP 10 months F317L 10/10
24 CP 9 months E255K 7/10
25 CP 38 months F359V 10/10
26 CP 25 months L387M 7/10
27 CP 25 months M244V 6/10
M351T 2/10
28 CP 20 months F317L 4/10
M351T 4/10
29 CP 17 months M351T 7/10
30 CP 17 months T315I 8/10
31 CP 33 months none n/a
32 CP 25 months M351T 4/10
H396R 4/10
33 P-MBC n/a T315I 2/10
M343T/F382L 2/10
34 P-MBC n/a E255K 2/10
35 P-MBC n/a none n/a
36 P-MBC n/a none n/a
37 NCR 14 months V379I 7/10
Duration of imatinib therapy at the time of analysis is shown. The fraction of independent clones for each mutation is given. Patients 2, 6, 8, 18, and 20
had major cytogenetic responses and patients 17 and 29 had minor cytogenetic responses prior to relapse, using criteria previously described (Kantarjian
et al., 2002). Patients 10, 13, and 31 had evidence of BCR-ABL gene amplification at relapse by FISH analysis. Patient 37 (NCR) harbors a kinase domain
mutation but has not suffered progressive disease (see also Figure 4). Eight additional NCR patients, as depicted in Figure 4, had no evidence of kinase
domain mutation, and are not represented here.
Abbreviations: MBC, relapsed myeloid blast crisis; LBC, relapsed lymphoid blast crisis; CP, relapsed chronic phase; P-MBC, preimatinib sample from myeloid
blast crisis patients whose disease was subsequently refractory; and NCR, chronic phase with hematologic response but no cytogenetic response.
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Figure 1. Summary of imatinib-resistant BCR-ABL
kinase domain mutations
Top: Schematic representation of the BCR-ABL
kinase domain. P loop (P), catalytic domain (C),
and activation loop (A) are depicted. Bottom:
Each letter represents a patient in whom the cor-
responding mutation was detected. Relapsed
chronic phase patients are represented by the
letter C (for exception, see below). Relapsed my-
eloid blast crisis patients are indicated by the
letter M. Patients with relapsed lymphoid blast
crisis are represented by the letter L. P indicates
mutations detected prior to imatinib treatment
in patients with myeloid blast crisis who exhibited
primary resistance to treatment. V379I was de-
tected in a single chronic phase patient with
persistence of the Philadelphia chromosome in
the setting of sustained hematologic response.
Note that kinase domain is not drawn to scale.
the closed conformation of the ABL activation loop, which is getic balance required to stabilize the closed conformation of
the activation loop (Figure 2C). Another cluster of mutationspart of a network of interactions that help stabilize the drug
binding site. In the closed conformation, Y393 in the activation involves amino acids located in the C-terminal lobe of the kinase
(E355, M351, and V379) in a region that provides a platform forloop is positioned such that it mimics the tyrosine residue of a
peptide substrate. The H396R substitution is located close to the base of the activation loop. While it is difficult to predict the
precise energetic consequences of mutations at these residues,Y393, such that mutations in this region might disturb the ener-
Figure 2. Proposed mechanisms of action of ima-
tinib-resistant mutations based upon the crystal
structure of ABL complexed with imatinib
A: Ribbon representation of the kinase domain of
ABL complexed to imatinib (Nagar et al., 2002),
depicting resistant mutations. Imatinib is shown
in gold. Positions 1–3 (red) are mutations that
directly affect imatinib binding. All other positions
are those that likely affect the ability of the kinase
to achieve the conformation required to bind
imatinib, including those in the P loop (4–8;
green) and those in the vicinity of the activation
loop (9–13; cyan). The activation loop is colored
purple. The positions of amino acids found mu-
tated are depicted by spheres: 1, F317; 2, T315;
3, F359; 4, M244; 5, G250; 6, Q252; 7, Y253; 8, E255;
9, M351; 10, E355; 11, V379; 12, L387; 13, H396.
B: Comparison of the P loop in the ABL:imatinib
structure (left) with that of active insulin receptor
kinase (IRK) (right) (Hubbard, 1997). Glu 255 in
the P loop (green) of ABL makes strong interac-
tions with Tyr 257 and Lys 247. The P loop is dis-
torted, with Tyr 253 swung into the ATP binding
site, forming a hydrophobic face against which
imatinib packs. In IRK, the P loop (blue) is folded
out over the nucleotide. Orange spheres indi-
cate Mg2 ions associated with nucleotide. Rep-
resentation constructed using a previously de-
scribed program (Evans, 1993). C: Mutations
located at sites that could influence conforma-
tional changes undergone by the activation
loop. For comparison, the activation loop of Lck
(an active tyrosine kinase) is shown in gold, in-
cluding the phosphorylated Tyr residue (pTyr 394)
(Yamaguchi and Hendrickson, 1996). Tyr 393, the
site of activating phosphorylation in ABL, is shown
in blue. Positions of mutations M351T, E355G,
V379I, L387M, and H396R are depicted as
spheres (cyan).
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all three are located adjacent to a region where large torsional hematologic relapse, we asked if similar mutations might be
found in cytogenetic nonresponders with sustained hematologicrotations are required to accommodate imatinib. Comparative
crystallographic studies of mutant ABL alleles are required to remissions. Four of 13 such chronic phase patients had muta-
tions. Three of these mutations (E255K, F317L, and F359V) areprecisely define the structural consequences of these muta-
tions. identical to those observed in cases of relapsed myeloid blast
crisis described above, whereas the fourth mutation (V379I) has
not been previously documented. We next asked if detectionMutant BCR-ABL alleles show varying degree
of imatinib resistance in vitro of a mutation during this time of stable hematologic response
correlated with clinical outcome. Three of the four patients withTo address the causal role of these mutations in imatinib resis-
tance, we generated mutant alleles by site-directed mutagene- kinase domain mutations suffered disease progression within
18 months of mutation detection, whereas only one of ninesis of wild-type BCR-ABL and expressed the mutants in the
interleukin-3 (IL-3)-dependent cell line Ba/F3. BCR-ABL activity patients without a detectable mutation progressed (Figure 4).
Of note, the patient without evidence for a kinase domain muta-has been shown to render Ba/F3 cells IL-3 independent (Daley
and Baltimore, 1988). The T315I and E255K mutations are tion had BCR-ABL gene amplification at relapse based on fluo-
rescence in situ hybridization analysis (data not shown). Theknown to confer IL-3 independence as well as biochemical and
biological resistance to imatinib in this system (Gorre et al., patient harboring the novel V379I mutation continues to have
a complete hematologic remission but no cytogenetic response2001a, 2002; von Bubnoff et al., 2002) and were included as
controls. Six previously uncharacterized mutants were chosen at 18 months. Although the number of patients is small, these
findings suggest that periodic assessment of the mutationalfor this initial analysis based on their frequency of isolation
and location within the kinase domain. IL-3-independent Ba/F3 status of the BCR-ABL kinase domain may have prognostic
utility.populations were derived for all six mutants studied, demonstra-
ting that each of these mutants retains biologic activity compa-
rable to wild-type BCR-ABL in this system. The effect of imatinib Evidence for clonal selection of preexisting BCR-ABL
kinase domain mutationsconcentrations ranging from 0.5 to 10 M on BCR-ABL kinase
activity and cellular viability was determined using standard The most frequent explanation for single-nucleotide substitu-
tions in the human genome are methylation-deamination reac-assays (Figure 3). As expected, the T315I and E255K mutants
were highly resistant to imatinib with IC50 values greater than tions that give rise to C/T or G/A transitions in the context of
the CpG dinucleotide sequence. This mechanism is estimated10-fold higher than wild-type BCR-ABL (Table 2). G250E-
expressing cells were also markedly resistant. Y253F also re- to account for about 25% of all reported nucleotide changes
based on comprehensive analysis of human genetic disorderssulted in considerable resistance, but clearly less than T315I,
consistent with another report that characterizes the effects of (Vogelstein and Kinzler, 1997). Remarkably, only 1 of the 15
mutations we observed (E255K) could be explained on thatthis same mutation on ABL kinase function (Roumiantsev et
al., 2002). Four mutations (Q252H, F317L, M351T, and E355G) basis. Alternatively, the high frequency of kinase domain muta-
tions observed in our study could reflect a global increase inconferred only moderate resistance to imatinib, retaining bio-
chemical sensitivity at drug concentrations of 1–4 M. Since mutation frequency (hypermutation) as a consequence of ge-
netic instability. To address this possibility, we looked for muta-drug levels approaching this concentration can be clinically
achieved in some patients, these results raise the possibility tions in other regions of the genome by sequencing a 700 bp
region of BCR-ABL immediately 5 to the kinase domain in fivethat resistance caused by certain mutations might respond to
high-dose imatinib treatment. The fact that all BCR-ABL mu- patients in whom kinase domain mutations were detected in a
large fraction of the original clones sequenced. No evidencetants tested show imatinib resistance in vitro provides strong
evidence that each of these mutations plays a causal role in of additional mutation was found in these samples. We also
assessed the kinase domain of the related tyrosine kinase KIT,clinical imatinib resistance. Biochemical characterization of the
five remaining mutations found, consisting of the novel muta- which resides on chromosome 4 and exhibits sensitivity to ima-
tinib at concentrations equivalent to BCR-ABL, in the sametions M244V, F359V, V379I, and L387M, in addition to the pre-
viously described H396R, will require additional studies. group of five patients. No evidence of KIT kinase domain muta-
tion was detected, arguing against a model of widespread geno-
mic instability.Potential predictive value of mutation detection
in patients with stable disease Another possible explanation for the high frequency of muta-
tions is that exposure to imatinib might induce genetic instability,The overwhelming majority of CML patients on imatinib therapy
have chronic phase disease. Although 90% of patients with particularly since the wild-type ABL kinase (which is also inhib-
ited by imatinib) has been implicated in DNA repair (Kharbandachronic phase CML achieve excellent hematologic control of
their disease with imatinib, about half of these patients continue et al., 1997; Shafman et al., 1997; Yoshida et al., 2002). Several
lines of evidence argue against this hypothesis. First, patientsto have a significant number of Ph chromosome-containing cells
in the bone marrow (“cytogenetic nonresponders”). Recent data with blast crisis CML often relapse within 1–3 months of initiating
imatinib therapy, providing a short window of time for the acqui-suggests that these patients progress to blast crisis more
quickly that those who obtain cytogenetic remissions (Kantarjian sition of mutations and expansion of a drug-resistant clone.
Second, we found multiple independent BCR-ABL mutationset al., 2002). The reason for failure to achieve a cytogenetic
response is unknown, but may involve incomplete inhibition of (2–4 clones per patient) in 12 of the 32 patients with imatinib
resistance, including 5 patients who relapsed within 3 monthsBCR-ABL kinase activity in progenitor cells or activation of BCR-
ABL-independent survival pathways. Since BCR-ABL kinase of starting therapy (Table 1). Unless we postulate an extremely
high mutation rate, these results are most consistent with adomain mutations are prevalent in imatinib-treated patients with
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Figure 3. BCR-ABL kinase domain mutants exhibit
varying degrees of biochemical and biological
resistance to imatinib
A: Western blot analysis using an anti-phospho-
tyrosine antibody (4G10) or anti-ABL antibody of
lysates prepared from IL-3-independent Ba/F3
populations infected with retroviruses expressing
the BCR-ABL isoforms indicated. Cells were ex-
posed to the concentrations of imatinib indi-
cated for 2 hr. B: Ba/F3 populations stably ex-
pressing mutant BCR-ABL isoforms were plated
in the presence of varying concentrations of im-
atinib in triplicate, and viable cell counts were
performed after 48 hr of exposure. Cell counts
were normalized to the number of viable cells
from control cultures grown in the absence of
imatinib.
model whereby mutant clones preexist in some patients at levels mutation, when engineered into ABL, has demonstrated onco-
genic activity (Allen and Wiedemann, 1996). The mechanism forbelow our threshold for detection, then expand under the selec-
tive pressure of imatinib treatment. Definitive evidence for this the underlying increase in genetic instability that presumably
leads to these mutations in CML cells remains to be defined.hypothesis was obtained by analysis of pretreatment samples
from four blast crisis patients who failed to achieve even a
transient response to imatinib (primary or de novo hematologic Discussion
resistance). One patient exhibited T315I prior to initiation of
therapy, as well as a separate BCR-ABL clone that contained In a comprehensive analysis of CML patients treated with ima-
tinib in all phases of the disease, we find that mutations in thetwo mutations, M343T and F382L, on the same DNA sequence.
A second patient had the E255K mutation (Table 1). Collectively, BCR-ABL kinase domain occur in over 90% of patients who
relapse after an initial response. The high frequency of mutationthese data indicate that BCR-ABL kinase domain mutations can
occur during the natural evolution of CML and that those capa- detection in our study relative to smaller studies reported by
other investigators is most likely explained by differences inble of conferring imatinib resistance expand under the selective
pressure of imatinib treatment. The fact that certain mutations assay sensitivity. By subcloning and sequencing ten indepen-
dent clones from each patient, we can reliably and confidentlycan be detected in a significant fraction of cells prior to imatinib
therapy suggest that some mutations may confer gain of func- detect mutant clones representing approximately 20% of the
total population of BCR-ABL-expressing cells. This strategy alsotion, analogous to a kinase domain mutation present in v-Abl,
which has been shown to contribute to its oncogenic potential allows detection of polyclonal resistance, which would be ex-
tremely difficult to find using direct sequencing methods (with-(Jackson et al., 1993). Members of the Src family of kinases,
which have increased kinase activity relative to ABL, all have a out subcloning) because the mixture of wild-type and mutant
clones would most likely be read as consensus wild-type se-phenylalanine at amino acid position 5 in the P loop, whereas
ABL has a tyrosine at this position. Furthermore, the Y253F quence. A second issue likely to explain differences in mutation
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Table 2. Summary of BCR-ABL kinase domain mutations, associated disease state(s) prior to imatinib therapy, biochemical and biologic properties, and
proposed mechanism of resistance
Mutation Phase of disease Biochemical IC50 (M) Biological IC50 (M) Proposed mechanism of resistance
M244V CP not assessed not assessed impairs conformational change (P loop)
G250E MBC 7.40 10 impairs conformational change (P loop)
Q252H/R MBC, LBC 2.93 3.12 impairs conformational change (P loop)
Y253F/H MBC, LBC 5.96 8.94 impairs conformational change (P loop)
E255K MBC, LBC, CP, P-MBC 7.81 10 impairs conformational change (P loop)
T315I MBC, LBC, CP, P-MBC 10 10 directly affects imatinib binding
F317L MBC, CP 3.30 7.50 directly affects imatinib binding
M351T MBC, LBC, CP 1.07 4.38 impairs conformational change (adjacent to activation loop)
E355G MBC 2.82 2.38 impairs conformational change (adjacent to activation loop)
F359V MBC, CP not assessed not assessed directly affects imatinib binding
V379I CP-NCR not assessed not assessed impairs conformational change (activation loop)
L387M CP not assessed not assessed impairs conformational change (activation loop)
H396R MBC, CP not assessed not assessed impairs conformational change (activation loop)
wild-type - 0.28 0.60 not applicable
Abbreviations: MBC, myeloid blast crisis; LBC, lymphoid blast crisis; CP, chronic phase; CP-NCR, chronic phase with hematologic response in the absence
of cytogenetic response (cytogenetic nonresponder).
frequency is patient selection, particularly if analysis is per- resistance do so by preventing the kinase domain from achiev-
ing the closed conformation necessary for imatinib binding (asformed on patients who fail to have a hematologic response to
imatinib. Having defined a large number of amino acid substitu- proposed in Figure 2), one can envision that inhibitors that bind
ABL in the open configuration might retain activity against manytions, we obtained definitive evidence from in vitro reconstitution
studies that at least eight mutants (all those studied to date) of these mutants. Indeed, we have evidence that the E255K
mutant remains sensitive to such a dual ABL/SRC inhibitor (M.play a causal role in imatinib resistance. The role of the remaining
seven (less common) mutations will need to be examined using Moasser, N. Rosen, M.E.G., and C.L.S., unpublished data). Al-
ternatively, it may be necessary to inhibit BCR-ABL signalingsimilar assays before definitive conclusions about these mutants
can be made. Our results reinforce the central role of BCR-ABL using completely different strategies that do not require binding
to the kinase domain. Possibilities include the induction of BCR-kinase activity in CML at all disease stages and clearly delineate
the challenge that future targeted therapeutic strategies for CML ABL protein degradation using inhibitors of the molecular chap-
erone Hsp90 or blockade of critical signal transduction eventsmust address.
Are there any obvious strategies that should be considered? that function downstream of BCR-ABL such as the RAF/MEK/
ERK and PI3K/AKT pathways. We have preclinical evidence inThe complex array of different mutations observed in these
patients makes it difficult to envision a single second generation support of the former strategy based on the fact that two Hsp90
inhibitors, geldanamycin and 17-AAG, have potent in vitro activ-ABL kinase inhibitor that would have activity against all mutants.
However, recent insights gained from structural analysis of ABL ity against the T315I and E255K BCR-ABL mutants (Gorre et
al., 2002).bound to imatinib versus a dual ABL/SRC inhibitor indicate that
two different inhibitors can bind to the same kinase in different As second generation inhibitors undergo development, it
may be useful now to measure the mutation status of the BCR-conformational states (Nagar et al., 2002; Schindler et al., 2000).
If a significant number of the mutations that cause imatinib ABL kinase domain in selected populations of CML patients
Figure 4. Kaplan-Meier analysis of time to pro-
gression in chronic phase CML patients with he-
matologic response despite lack of cytogenetic
response
Thirteen chronic phase patients treated at UCLA
with imatinib who had sustained hematologic
response in the absence of cytogenetic re-
sponse were studied. Patients were categorized
with respect to the presence of BCR-ABL kinase
domain mutations at the time of analysis. Pro-
gression is defined as loss of previously achieved
hematologic response to imatinib. The four pa-
tients who progressed were reevaluated for the
presence of mutation at the time of progression.
Data obtained at the time of progression is in-
cluded in Table 1 (patients 23–25, 31). The one
patient with a kinase domain mutation who did
not have disease progression is also listed in Table
1 (patient 37). P value obtained by exact logrank
test.
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The kinase domain of c-KIT was amplified using the following primers:treated with imatinib. Our analysis of a small number of chronic
5-TGAGGAGATAAATGGAAACAA-3 and 5-AACTCGTCATCCTCCATGAT-3.phase patients with stable hematologic control but no cytoge-
To control for the number of cycles used for the BCR-ABL kinase domain,netic response suggests that detection of such mutants por-
a second amplification was performed; the resultant 0.6 kb fragment was
tends a poor prognosis. If this result is confirmed in a larger subcloned into pBluescript II KS and ten independent clones were se-
prospective trial, one can envision altering the clinical manage- quenced.
ment of such patients by imatinib dose escalation (if the mutation Expression vectors of mutant P210 isoforms were created as follows.
Oligonucleotides representing various point mutations were synthesized byis one that confers partial imatinib resistance), addition of a
GIBCO-BRL. pSRP210BCR-ABL was used as the template DNA for site-second agent such as interferon, early consideration of alloge-
directed mutagenesis reactions utilizing the mutant oligonucleotides andneic stem cell transplantation, or enrollment in an experimental
the QuikChange mutagenesis kit (Stratagene). Successful mutagenesis was
drug trial. Widespread testing for such mutations would clearly confirmed by sequence analysis of the kinase domain.
require a less cumbersome method for mutation detection than 293T cells maintained in DMEM with 10% fetal calf serum were cotrans-
that described here, perhaps using mutation-specific assays. fected by the calcium phosphate method with mutant P210 expression
vectors and a packaging plasmid (Ecopack, kindly provided by R. van Etten).The fact that only three mutations (T315I, E255K, and M351T)
Media containing virus was filtered and used to infect Ba/F3 cells grown inaccount for more that 60% of the cases in our study provides
RPMI supplemented with 10% fetal calf serum and IL-3. Stable lines werea starting point for the development of such clinical tests.
selected in the presence of G418 and IL-3. After 48 hr, cells were washedThe long-range outlook for managing imatinib resistance
thrice in PBS and subsequently grown in the absence of IL-3. Expression
should focus on defining the mechanism by which kinase do- of BCR-ABL was documented by Western blot analysis. To determine the
main mutations occur so that the emergence of resistant clones biochemical sensitivity of mutant BCR-ABL P210 isoforms to imatinib, cells
were incubated in the presence of imatinib (kindly provided by Novartismight be prevented. Our sequencing analysis provides very
Pharmaceuticals) at 0, 0.5, 1, 5, and 10 micromoles per liter. After 2 hr oflittle evidence for methylation-deamination or hypermutation as
incubation, cell lysates were prepared in 12.5 mM EDTA (pH 8.0), 25 mMfactors that lead to the high frequency of mutations. By default,
HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 g/mlwe assume that CML cells have increased genomic instability,
aprotinin, 100 g/ml PMSF, and 2 g/ml leupeptin. Seventy-five micrograms
as is clearly evident in blast crisis where a range of secondary of total protein were analyzed by Western blot using anti-ABL antibody AB-3
chromosomal changes are frequently observed. The fact that (Oncogene Research Products) or anti-phosphotyrosine antibody 4G10 (Up-
mutations are also found in chronic phase patients (who have state Biochemicals). Quantification of the 210 kDa signal was achieved using
ImageQuant 5.0 (Microsoft) densitometry. Tyrosine-phosphorylated BCR-normal karyotypes except for the Ph chromosome) argues for
ABL was normalized to the amount of P210 signal detected with anti-ABLadditional genetic instability early in the disease. Indeed, there
antibody. Normalized phospho-BCR-ABL values were plotted for each mu-is some experimental evidence that expression of BCR-ABL
tant, and biochemical IC50 was determined following creation of a best-fitcan induce genetic instability in mouse models (Salloukh and
curve. Mutant Q252H was not adequately detected by AB-3 and phospho-
Laneuville, 2000). Until the mechanism responsible for the devel- BCR-ABL was therefore not normalized. To determine the biological sensitiv-
opment of these mutations is defined, it seems likely that future ity to imatinib, 1  105 exponentially growing Ba/F3 cells/ml expressing
targeted therapy of CML will follow the model currently in prac- various isoforms of BCR-ABL P210 were grown in RPMI supplemented with
10% fetal calf serum and incubated in the presence of imatinib at 0, 0.1,tice for the treatment of HIV—combination therapy with multiple
0.5, 1, 5, and 10 micromoles per liter. Exposure to imatinib was performedtargeted agents.
in triplicate. After 24, 48, and 72 hr of incubation, live cells were quantitated
by trypan blue stain exclusion. The mean number of viable cells at varyingExperimental procedures
concentrations was normalized to mean value of viable cells in the 0 mM
imatinib sample. Biological IC50 was determined from semilogarithmic graph-After obtaining informed consent to participate in a research protocol ap-
ing of the 48 hr time point for each mutant.proved by the UCLA institutional review board, blood or bone marrow sam-
ples were obtained from patients enrolled in clinical trials assessing the
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